Current Controversies in Chronic Obstructive Pulmonary Disease. A Report from the Global Initiative for Chronic Obstructive Lung Disease Scientific Committee.

Published on Jan 1, 2019in Annals of the American Thoracic Society6.831
· DOI :10.1513/ANNALSATS.201808-557PS
Rong‑Chang Chen17
Estimated H-index: 17
 (Guangzhou Medical University)
Sources
Abstract
References131
Newest
Rationale: The relationship between longitudinal lung function trajectories, chest computed tomography (CT) imaging, and genetic predisposition to chronic obstructive pulmonary disease (COPD) has n...
Source
Jul 1, 2018·The Lancet Respiratory Medicine30.70
#1Dinh S Bui (Hanoi University)H-Index: 8
#2Caroline J Lodge (University of Melbourne)H-Index: 34
Last. Shyamali C. Dharmage (University of Melbourne)H-Index: 76
view all 27 authors...
Summary Background Lifetime lung function is related to quality of life and longevity. Over the lifespan, individuals follow different lung function trajectories. Identification of these trajectories, their determinants, and outcomes is important, but no study has done this beyond the fourth decade. Methods We used six waves of the Tasmanian Longitudinal Health Study (TAHS) to model lung function trajectories measured at 7, 13, 18, 45, 50, and 53 years. We analysed pre-bronchodilator FEV 1 z-sco...
Source
Apr 18, 2018·The New England Journal of Medicine91.25
#8David M.G. Halpin (JHUSOM: Johns Hopkins University School of Medicine)
Abstract Background The benefits of triple therapy for chronic obstructive pulmonary disease (COPD) with an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long-acting β2-agonist (LABA), as compared with dual therapy (either inhaled glucocorticoid–LABA or LAMA–LABA), are uncertain. Methods In this randomized trial involving 10,355 patients with COPD, we compared 52 weeks of a once-daily combination of fluticasone furoate (an inhaled glucocorticoid) at a dose of 100 μg, ...
Source
Mar 17, 2018·The Lancet79.32
#1Alberto Papi (University of Ferrara)H-Index: 97
#2Jørgen Vestbo (University of Manchester)H-Index: 121
Last. Dave Singh (University of Manchester)H-Index: 80
view all 13 authors...
Summary Background Evidence is scarce on the relative risk-benefit of inhaled triple therapy, consisting of inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting β 2 -agonist, versus dual bronchodilation for chronic obstructive pulmonary disease (COPD). We aimed to compare a single-inhaler triple combination of beclometasone dipropionate, formoterol fumarate, and glycopyrronium (BDP/FF/G) versus a single-inhaler dual bronchodilator combination of indacaterol plus glycopyrron...
Source
Feb 1, 2018·The Lancet Respiratory Medicine30.70
#1Mona Bafadhel (University of Oxford)H-Index: 30
#2Stefan PetersonH-Index: 17
Last. Malin Fagerås (AstraZeneca)H-Index: 9
view all 7 authors...
Summary Background The peripheral blood eosinophil count might help identify those patients with chronic obstructive pulmonary disease (COPD) who will experience fewer exacerbations when taking inhaled corticosteroids (ICS). Previous post-hoc analyses have proposed eosinophil cutoffs that are both arbitrary and limited in evaluating complex interactions of treatment response. We modelled eosinophil count as a continuous variable to determine the characteristics that determine both exacerbation r...
Source
Jan 1, 2018·ERJ Open Research
#1Bartolome R. Celli (Brigham and Women's Hospital)H-Index: 131
#2Alvar Agusti (University of Barcelona)H-Index: 120
Due to well-conducted epidemiological studies and advances in genetics, molecular biology, translational research, the advent of computed tomography of the lungs and bioinformatics, the diagnosis of chronic obstructive pulmonary disease (COPD) as a single entity caused by susceptibility to cigarette smoke is no longer tenable. Furthermore, the once-accepted concept that COPD results from a rapid and progressive loss of lung function over time is not true for a sizeable proportion of adults with ...
Source
Jan 1, 2018·European Respiratory Journal16.67
#1Thomas Southworth (University of Manchester)H-Index: 15
#2Gussie Beech (University of Manchester)H-Index: 2
Last. Dave Singh (University of Manchester)H-Index: 80
view all 5 authors...
Background: Clinical trials have shown that higher blood eosinophil counts in COPD patients predict a greater effect of inhaled corticosteroids (ICS) on exacerbation prevention; ICS effects increase incrementally with higher eosinophil counts. There is no current consensus on what thresholds should be used in clinical practice, but 150 eosinophils/μL may be suitable as values below this predict little or no ICS response. Reproducibility of biomarkers needs to be established before clinical use. ...
Source
Jan 1, 2018·American Journal of Respiratory and Critical Care Medicine21.41
#1Miranda Kirby (UBC: University of British Columbia)H-Index: 26
#2Naoya Tanabe (UBC: University of British Columbia)H-Index: 18
Last. Harvey O. CoxsonH-Index: 85
view all 11 authors...
Rationale: Studies of excised lungs show that significant airway attrition in the “quiet” zone occurs early in chronic obstructive pulmonary disease (COPD).Objectives: To determine if the total number of airways quantified in vivo using computed tomography (CT) reflects early airway-related disease changes and is associated with lung function decline independent of emphysema in COPD.Methods: Participants in the multicenter, population-based, longitudinal CanCOLD (Canadian Chronic Obstructive Lun...
Source
Dec 15, 2017·American Journal of Respiratory and Critical Care Medicine21.41
#1Gerard J. Criner (TU: Temple University)H-Index: 81
#2Richard SueH-Index: 3
Last. Dirk-Jan Slebos (UMCG: University Medical Center Groningen)H-Index: 46
view all 28 authors...
Rationale: Single-center randomized controlled trials of the Zephyr endobronchial valve (EBV) treatment have demonstrated benefit in severe heterogeneous emphysema. This is the first multicenter study evaluating this treatment approach.Objectives: To evaluate the efficacy and safety of Zephyr EBVs in patients with heterogeneous emphysema and absence of collateral ventilation.Methods: This was a prospective, multicenter 2:1 randomized controlled trial of EBVs plus standard of care or standard of ...
Source
Dec 1, 2017·Chest9.41
#1Fernando J. Martinez (Cornell University)H-Index: 151
#2Leonardo M. Fabbri (University of Modena and Reggio Emilia)H-Index: 124
Last. Colin Reisner (AstraZeneca)H-Index: 19
view all 7 authors...
Background The clinical severity of COPD is currently categorized by symptom burden and exacerbation risk. Previous 24-week phase III trials (NCT01854645 and NCT01854658) that demonstrated better improvement of lung function with glycopyrrolate/formoterol fumarate (GFF) metered dose inhaler (MDI) (an MDI fixed-dose of GFF 18/9.6 μg) over individual monocomponent MDIs included a cross-section of patients with moderate to very severe airflow limitation and a broad range of COPD symptoms. Methods T...
Source
12345678910
Cited By8
Newest
Source
#1Katsuyuki TakedaH-Index: 59
#2Soohyun KimH-Index: 51
Last. Erwin W. GelfandH-Index: 117
view all 5 authors...
Source
Source
Feb 1, 2020·The Lancet Respiratory Medicine30.70
#1Gerard J. Criner (TU: Temple University)H-Index: 81
#2Bartolome R. Celli (Brigham and Women's Hospital)H-Index: 131
Last. Paul Newbold (AstraZeneca)H-Index: 25
view all 12 authors...
Summary Background Benralizumab did not significantly reduce exacerbations compared with placebo in the phase 3 GALATHEA and TERRANOVA trials of benralizumab for patients with chronic obstructive pulmonary disease (COPD). We aimed to identify clinical and physiological characteristics of patients with COPD that could help to identify people who are likely to have the greatest treatment effect with benralizumab. Methods We analysed individual study and pooled results from GALATHEA and TERRANOVA. ...
Source
Feb 1, 2020·Respirology6.42
#1Peter Frith (Flinders University)H-Index: 43
Source
Jan 15, 2020·Scientific Reports4.38
#1Shuang Bai (PRC: China Medical University (PRC))H-Index: 2
#2Rui Ye (PRC: China Medical University (PRC))H-Index: 4
Last. Li Zhao (PRC: China Medical University (PRC))H-Index: 4
view all 5 authors...
Emphysematous smokers with normal spirometry form a considerable proportion of the clinical population. However, despite presenting with respiratory symptoms and activity limitation, they cannot be diagnosed with chronic obstructive lung disease (COPD) according to current criteria. Thus, we aimed to determine whether emphysema in smokers has a different pathogenesis from that in patients with COPD. We compared 12 pairs of lung tissue samples from emphysematous patients with normal spirometry an...
Source
#1Ruby Shah (Houston Methodist Hospital)
COPD and dementia are often treated together, and it is important to arm the practitioner with tools in the primary care setting. Diagnosis can be a challenge as pulmonary function tests (PFTs) are less accurate in memory loss, and caregiver report may be more reliable than patient reported symptoms. We recommend assessing cognitive ability before ordering PFTs while also interpreting results with age-related changes in mind. Periodically testing cognitive ability as well as functional status ca...
Source
Jul 13, 2019·European Journal of Internal Medicine4.62
#1Salvatore FuschilloH-Index: 9
#2Antonio Molino (University of Naples Federico II)H-Index: 22
Last. Mauro ManiscalcoH-Index: 28
view all 5 authors...
Abstract Disease phenotyping is a key step towards an increasingly personalized approach to chronic obstructive pulmonary disease (COPD), leading to a more precise assessment, treatment and definition of disease outcomes. The search for biomarkers able to guide the identification of COPD phenotypes are of great importance for both researchers and clinicians. However, while several biomarkers of inflammation [e.g., peripheral blood eosinophils and fractional expired nitric oxide] have been identi...
Source
1
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.